Related Experiment Video
Updated: Jul 17, 2026
07:25
Two-Photon Intravital Microscopy of Glioblastoma in a Murine Model
Published on: March 1, 2024
Gamma knife surgery for metastatic brainstem tumors
Chun Po Yen1, Jason Sheehan, Greg Patterson
1Lars Leksell Center for Gamma Surgery, Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA. ls9e@virginia.edu
Journal of Neurosurgery
|January 16, 2007
Summary
Gamma Knife surgery (GKS) offers a low-risk treatment option that prolongs survival for patients with metastatic brainstem tumors. Systemic disease severity is the primary factor influencing patient prognosis.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Metastatic brainstem tumors present a significant clinical challenge.
- Effective treatment strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the imaging and clinical outcomes of patients with metastatic brainstem tumors treated with Gamma Knife surgery (GKS).
Main Methods:
- Retrospective review of 53 patients with metastatic brainstem lesions treated with GKS between 1989 and 2005.
- Analysis of tumor response, symptom changes, and survival rates post-GKS.
- Correlation of prognostic factors with patient survival.
Main Results:
- Tumor shrinkage or disappearance observed in 29 of 37 evaluable patients.
- Symptomatic improvement in 21 of 35 patients with symptomatic brainstem deposits.
- Overall median survival of 11 months post-GKS; absence of active extracranial disease was a favorable prognostic factor.
Conclusions:
- Gamma Knife surgery (GKS) prolongs survival compared to natural disease progression for metastatic brainstem tumors.
- GKS is associated with low treatment-related risks.
- Prognosis is largely determined by the severity of the patient's systemic disease.
